The DESTINY-Breast04 trial (ClinicalTrials.gov identifer: NCT03734029 and DB-06; NCT04494425), which focusses on HER2-low metastatic BC, could also present first positive data in comparison to treatment with chemotherapies of physicians’ choice. This evidence concerns the gene ERBB2 and breast cancer.